TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31668830

Group type: EXPERIMENTAL
Intervention: THC (15 mg oral)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 24
Study: 31669004

Group type: EXPERIMENTAL
Intervention: 5-min steady-state (SS) approach for estimating resting energy expenditure (REE) using indirect calorimetry
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 4-min and 3-min SS periods, or fixed time intervals of at least 5 min
Number of subjects: 64
Study: 31669155

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily (escalating doses of 10 mg once daily to 100 mg twice daily in phase 1 only)
Number of subjects: 69
Study: 31669560

Group type: EXPERIMENTAL
Intervention: Robotic-assisted hernia repair
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Open hernia repair
Number of subjects: 200
Study: 31670288

Group type: EXPERIMENTAL
Intervention: Phosphorus-32 microparticles with EUS guidance in combination with gemcitabine ± nab-paclitaxel
Number of subjects: 0
Study: 31670336

Group type: EXPERIMENTAL
Intervention: DWS with 25% faba bean flour (FBF)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: DWS with 25% starch concentrate (FBS)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: DWS with 25% protein concentrate (FBPC)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: DWS with 25% protein isolate (FBPI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: DWS alone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 54
Study: 31670431

Group type: EXPERIMENTAL
Intervention: Mobile phone-based reporting of sense of coherence (SOC)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mobile phone-based reporting of health-related quality of life (HRQOL) using FACT-G
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mobile phone-based reporting of neurotoxicity using OANQ
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mobile phone-based reporting of physical wellbeing
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mobile phone-based reporting of social wellbeing
Number of subjects: 43
Study: 31670483

Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) encompassing eight SNPs in seven genes
Number of subjects: 1000
Study: 31670697

Group type: EXPERIMENTAL
Intervention: Clinical examination for estimating cardiac function
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Noradrenaline administration
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Presence of delayed capillary refill time or mottling
Number of subjects: 1075
Study: 31670928

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Age (per 1 year increase)
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Admission Alberta Stroke Program Early CT Score (per a decrease of 1 point)
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Angiographic poor collaterals
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Embolization in new territory
Number of subjects: 1316
Study: 31671877

Group type: EXPERIMENTAL
Intervention: Dose Intensive Rituximab and High-Dose Methylprednisolone
Number of subjects: 0
Study: 31672031

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 8582

Group type: EXPERIMENTAL
Intervention: Current smokers with HPR
Number of subjects: 8582

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 8582

Group type: EXPERIMENTAL
Intervention: High on-treatment platelet reactivity (HPR)
Number of subjects: 8582
Study: 31672100

Group type: EXPERIMENTAL
Intervention: Early LV recovery (within 10 days after the acute event)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Late LV improvement (after 10 days)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Patients without early recovery
Number of subjects: 406
Study: 31672144

Group type: EXPERIMENTAL
Intervention: BSL ≥ 11.1 mmol/L
Number of subjects: 2168

Group type: EXPERIMENTAL
Intervention: Cyr61 biomarker
Number of subjects: 2168

Group type: EXPERIMENTAL
Intervention: History of diabetes and elevated entry glucose
Number of subjects: 2168

Group type: COMPARATOR
Intervention: BSL < 6.0 mmol/L or 6.0-11.1 mmol/L
Number of subjects: 2168
Study: 31672148

Group type: EXPERIMENTAL
Intervention: PCSK9 quartile I (< 136 ng/mL)
Number of subjects: 539

Group type: COMPARATOR
Intervention: PCSK9 quartile IV (> 266 ng/mL)
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: PCSK9 levels
Number of subjects: 539
Study: 31672665

Group type: EXPERIMENTAL
Intervention: Serial RT-PCR for ZIKV and DENV at 3 timepoints between days 3 and 13 of symptom onset
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serial serology measurements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manufacturers cutoffs for serology
Number of subjects: 0
Study: 31672853

Group type: EXPERIMENTAL
Intervention: Combination of PIVKA-II and AFP
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nomogram including AFP, PIVKA-II, age, and sex
Number of subjects: 11
Study: 31672925

Group type: EXPERIMENTAL
Intervention: Educational level
Number of subjects: 164
Study: 31673295

Group type: EXPERIMENTAL
Intervention: 100-µg vitamin D for 3 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 48
Study: 31673391

Group type: EXPERIMENTAL
Intervention: tocilizumab
Number of subjects: 200

Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 200
Study: 31673387

Group type: EXPERIMENTAL
Intervention: Balloon aortic valvuloplasty (BAV)
Number of subjects: 196

Group type: COMPARATOR
Intervention: No balloon aortic valvuloplasty (BAV)
Number of subjects: 196
Study: 31673398

Group type: EXPERIMENTAL
Intervention: Health TAPESTRY-HC-DM intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 31673393

Group type: EXPERIMENTAL
Intervention: USPIO (ferumoxytol, 4 mg/kg) infusion
Number of subjects: 11
Study: 31673415

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg subcutaneously once every 2 weeks
Number of subjects: 320
Study: 31673422

Group type: EXPERIMENTAL
Intervention: CANDEN MRI spine inflammation score
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CANDEN MRI spine fat score
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CANDEN MRI spine bone erosion score
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CANDEN MRI spine new bone formation score
Number of subjects: 40
Study: 31673426

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) delivered to the target lesion with a cumulative dose of 114 Gy (equivalent dose in 2 Gy with an alpha to beta ratio of 2.6).
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control lesion (untreated lesion).
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a fraction size of 10 Gy or greater.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT).
Number of subjects: 17
Study: 31673900

Group type: EXPERIMENTAL
Intervention: Cancer therapeutics associated with arrhythmias
Number of subjects: 0
Study: 31673946

Group type: EXPERIMENTAL
Intervention: Zero-heat-flux sensor (3M Bair Hugger Temperature monitoring system, ZHF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Esophageal thermometer
Number of subjects: 0
Study: 31673978

Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS) lavage after puncture and lavage of calcification
Number of subjects: 17
Study: 31675266

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0
Study: 31675683

Group type: EXPERIMENTAL
Intervention: HER2+ subtype
Number of subjects: 10595

Group type: EXPERIMENTAL
Intervention: TNBC subtype
Number of subjects: 10595

Group type: EXPERIMENTAL
Intervention: Short TFMR
Number of subjects: 10595

Group type: EXPERIMENTAL
Intervention: Long-term survivors
Number of subjects: 10595

Group type: EXPERIMENTAL
Intervention: Median TFMR
Number of subjects: 10595
Study: 31675925

Group type: EXPERIMENTAL
Intervention: Integrated care for cardiovascular risk management (CVRM)
Number of subjects: 740

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 740
Study: 31675952

Group type: EXPERIMENTAL
Intervention: Capecitabine 850 mg/m2, P.O. bid, days 1-14, and ziv-aflibercept 6 mg/kg I.V., day 1, of each 21-day cycle
Number of subjects: 50

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 50
Study: 31676085

Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31676206

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) task of decision making to acquire or discard material possessions
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Non-decision making task contrast
Number of subjects: 79
Study: 31676359

Group type: EXPERIMENTAL
Intervention: SNP-adjusted tests for CA19-9
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: CA19-9 levels greater than SNP-determined cut-off values
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Combination of CA19-9 and CEA
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Combination of CA19-9 and CA-125
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Combination of CA19-9 and thrombospondin-2
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: SNPs for CEA and CA-125
Number of subjects: 504
Study: 31676653

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial (SBT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mechanical ventilation (MV)
Number of subjects: 20
Study: 31676905

Group type: EXPERIMENTAL
Intervention: Delamanid-containing regimens
Number of subjects: 0
Study: 31676976

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Routine pulmonary function testing
Number of subjects: 27
Study: 31677135

Group type: EXPERIMENTAL
Intervention: Automated echocardiographic method
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Manual echocardiographic method
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous pulmonary artery thermodilution technique
Number of subjects: 50
Study: 31678032

Group type: EXPERIMENTAL
Intervention: LRRK2 non-manifesting carriers
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: GBA non-manifesting carriers
Number of subjects: 392
Study: 31678093

Group type: EXPERIMENTAL
Intervention: Hysteroscopic myomectomy
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Abdominal myomectomy
Number of subjects: 1206
Study: 31678203

Group type: EXPERIMENTAL
Intervention: Magnetically assisted capsule endoscopy (MACE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Endoscopy (EGD)
Number of subjects: 50
Study: 31678408

Group type: EXPERIMENTAL
Intervention: Cardiac arrest (CA) patients
Number of subjects: 1561

Group type: COMPARATOR
Intervention: Non-cardiac arrest (non-CA) patients
Number of subjects: 1561
Study: 31678768

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 31678771

Group type: EXPERIMENTAL
Intervention: Everolimus after hepatic arterial embolisation therapy (HAET)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Everolimus after HAET
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: HAET and everolimus
Number of subjects: 74
Study: 31678861

Group type: EXPERIMENTAL
Intervention: Transdiagnostic Sleep and Circadian Intervention (TranS-C)
Number of subjects: 64
Study: 31679129

Group type: EXPERIMENTAL
Intervention: New injectable treatment for T2DM
Number of subjects: 7
Study: 31679176

Group type: EXPERIMENTAL
Intervention: Molecular assessment of mucosal biopsies (3BMBs) using unsupervised machine learning algorithms to classify rejection-related phenotypes.
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Rejection phenotype scoring based on expression of rejection-associated transcripts.
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Assessment of late inflammation phenotype in 3BMBs.
Number of subjects: 243
Study: 31679507

Group type: EXPERIMENTAL
Intervention: PAHEPI program (Treatment 1)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: PAHEPI + school meals (Treatment 2)
Number of subjects: 320
Study: 31679701

Group type: EXPERIMENTAL
Intervention: Ultrasonic vessel-sealing device
Number of subjects: 150

Group type: COMPARATOR
Intervention: Endostaplers
Number of subjects: 150
Study: 31679960

Group type: EXPERIMENTAL
Intervention: N170 response to faces
Number of subjects: 77

Group type: COMPARATOR
Intervention: Social skills intervention
Number of subjects: 77
Study: 31680143

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Cytotoxic agents
Number of subjects: 136
Study: 31680746

Group type: EXPERIMENTAL
Intervention: Capsulotomy with capsular conservation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Capsulectomy
Number of subjects: 2
Study: 31680935

Group type: EXPERIMENTAL
Intervention: State-of-the-art MRI techniques for measuring cerebrovascular reactivity (CVR) in large intracranial vessels.
Number of subjects: 0
Study: 31681030

Group type: EXPERIMENTAL
Intervention: Automatic 3D analysis
Number of subjects: 0
Study: 31681165

Group type: EXPERIMENTAL
Intervention: Osteocalcin (OC) levels
Number of subjects: 99
Study: 31681600

Group type: EXPERIMENTAL
Intervention: Cisplatin-radiotherapy with triapine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cisplatin-radiotherapy without triapine (control)
Number of subjects: 26
Study: 31682550

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg once every 3 weeks for 2 years or until disease progression, unacceptable toxicity, or patient withdrawal
Number of subjects: 233
Study: 31682588

Group type: EXPERIMENTAL
Intervention: Resistance exercise with blood flow restriction (KAATSU training) at 20% of 1 repetition maximum for 12 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional resistance exercise at 60% of 1 repetition maximum for 12 weeks
Number of subjects: 26
Study: 31682827

Group type: EXPERIMENTAL
Intervention: Multi-modal MRI
Number of subjects: 0
Study: 31682879

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir for 8 weeks
Number of subjects: 343
Study: 31682968

Group type: EXPERIMENTAL
Intervention: MRI- and PET-guided interstitial brachytherapy
Number of subjects: 60
Study: 31684094

Group type: EXPERIMENTAL
Intervention: High dose (HD) intravenous furosemide (greater than 125 mg)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Low dose (LD) intravenous furosemide (less than 125 mg)
Number of subjects: 121
Study: 31684877

Group type: EXPERIMENTAL
Intervention: Anesthesia induction with midazolam, sufentanil, and rocuronium, followed by sevoflurane, with positive pressure ventilation (PEEP 5, tidal volume 6-8 ml/kg)
Number of subjects: 53
Study: 31684886

Group type: EXPERIMENTAL
Intervention: Pain management and exercise interventions
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Walking speed
Number of subjects: 149
Study: 31684919

Group type: EXPERIMENTAL
Intervention: Precarious patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-precarious patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Geographical information systems method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anthropological analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic analysis
Number of subjects: 0
Study: 31684927

Group type: EXPERIMENTAL
Intervention: Curcumin (400 mg in enhanced absorption formulation)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non-hydrolyzed plasma samples
Number of subjects: 8
Study: 31684993

Group type: EXPERIMENTAL
Intervention: LINAC VMAT (AAA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LINAC VMAT (AXB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cyberknife
Number of subjects: 10
Study: 31685074

Group type: EXPERIMENTAL
Intervention: Alcohol testing
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo testing
Number of subjects: 294
Study: 31685415

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 19
Study: 31685467

Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion (TCI) of cefepime, median duration of 4.5 days, targeting a blood concentration of 16 mg/liter
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard of care for cefepime (not specified in detail)
Number of subjects: 21
Study: 31685468

Group type: EXPERIMENTAL
Intervention: Telavancin; specific dosage and duration not mentioned
Number of subjects: 0
Study: 31685476

Group type: EXPERIMENTAL
Intervention: Artefenomel and DSM265 combination treatment
Number of subjects: 0
Study: 31685491

Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine at doses 15 to 200 μg/kg every 3 weeks
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine at doses ≥120 μg/kg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine (all doses)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine at doses ≥150 μg/kg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Number of subjects: 88
Study: 31685499

Group type: EXPERIMENTAL
Intervention: Magnesium consumption in quintiles Q2-Q5
Number of subjects: 6473

Group type: COMPARATOR
Intervention: Total magnesium intake
Number of subjects: 6473
Study: 31685501

Group type: EXPERIMENTAL
Intervention: Midwife-led continuity model of care
Number of subjects: 200

Group type: COMPARATOR
Intervention: Regular maternity care
Number of subjects: 200
Study: 31685513

Group type: EXPERIMENTAL
Intervention: Routine intervention aimed at improving physical activity (PA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Wrist-worn accelerometers (Axivity AX3)
Number of subjects: 35
Study: 31685527

Group type: EXPERIMENTAL
Intervention: Transpyloric feeding
Number of subjects: 15

Group type: COMPARATOR
Intervention: Gastric feeding
Number of subjects: 15
Study: 31685558

Group type: EXPERIMENTAL
Intervention: Rucaparib (poly(ADP-ribose) polymerase inhibitor) as monotherapy
Number of subjects: 79
Study: 31685586

Group type: EXPERIMENTAL
Intervention: Non-menthol cigarettes for 2 weeks
Number of subjects: 29
Study: 31686036

Group type: EXPERIMENTAL
Intervention: Atezolizumab (neoadjuvant treatment)
Number of subjects: 0
Study: 31686289

Group type: EXPERIMENTAL
Intervention: General Practitioners (GPs) involvement in decision-making process
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Communication with families post-decision
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Perception of GPs on their involvement
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Desire for involvement in end of life decisions
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Perception of end of life management in ED
Number of subjects: 109
Study: 31686573

Group type: EXPERIMENTAL
Intervention: Supera Interwoven Nitinol Stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare Nitinol Stents
Number of subjects: 0
Study: 31687050

Group type: EXPERIMENTAL
Intervention: Galectin-3 (Gal-3)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Soluble ST2 (sST2)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Echocardiographic parameters
Number of subjects: 117
Study: 31687203

Group type: EXPERIMENTAL
Intervention: 1 dose of Ranibizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 loading doses of Ranibizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pro Re Nata regimen using Ranibizumab
Number of subjects: 0
Study: 31687205

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 60
Study: 31687922

Group type: EXPERIMENTAL
Intervention: Percutaneous CT-guided irreversible electroporation (IRE)
Number of subjects: 0
Study: 31688003

Group type: EXPERIMENTAL
Intervention: Optical device for blood pressure estimation (Aktiia OBPM algorithms)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Radial artery catheterization (reference method)
Number of subjects: 31
Study: 31688330

Group type: EXPERIMENTAL
Intervention: RER calculated at the end of surgery
Number of subjects: 110
Study: 31688340

Group type: EXPERIMENTAL
Intervention: Face-to-face contact in the transplant clinic
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Online transplant newsletter
Number of subjects: 60

Group type: COMPARATOR
Intervention: Facebook and university website
Number of subjects: 60
Study: 31688526

Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic sacrocolpopexy using very lightweight polypropylene Y-mesh
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Subsequent POP repair (5 native tissue anterior repairs and 5 native tissue posterior repairs)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Use of a pessary for recurrent anterior POP
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: No further prolapse treatment
Number of subjects: 253
Study: 31688824

Group type: EXPERIMENTAL
Intervention: REPLETED (IVCD ≥ 10 mm)
Number of subjects: 144

Group type: COMPARATOR
Intervention: NONREPLETED (IVCD < 10 mm)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: IVCDMIN
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: IVCCI
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: IJVDMIN
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: IJVCI
Number of subjects: 144
Study: 31689009

Group type: EXPERIMENTAL
Intervention: 3D Optical Scanning (3DO)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Dual-energy x-ray absorptiometry
Number of subjects: 181
Study: 31689155

Group type: EXPERIMENTAL
Intervention: DSTP3086S (2.4 mg/kg once every 3 weeks)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: DSTP3086S (doses > 2 mg/kg once every 3 weeks)
Number of subjects: 84

Group type: COMPARATOR
Intervention: DSTP3086S (weekly dosing)
Number of subjects: 84